A NEW CLINICAL TRIAL OPPORTUNITY
A new oral medication called ARAMIS is being evaluated in men who have rising PSA levels on Lupron and whose bone scans remain clear. For more information, visit: https://clinicaltrials.gov/show/NCT02200614
ARAMIS is similar to Xtandi but may have some advantages because ARAMIS is less likely to affect brain function which could reduce the likelihood of seizures and side effects such as fatigue which are potential side effects from Xtandi. Two out of every 3 men in this study will be randomly assigned to receive investigational medication.
The purpose of the study is to determine the safety and efficacy of ARAMIS in delaying prostate cancer from spreading outside of the prostate.
To be eligible to participate in the trial men must:
- Have a PSA rising quickly enough to double in less than 10 months
- No previous treatment with Xtandi or Zytiga
- No prior chemotherapy or immunotherapy for prostate cancer.
- Overall reasonably good health without serious heart problems.
If you are currently receiving hormone therapy, your treatment will continue and in addition you will receive either the investigational medication or placebo. Two out of every 3 patients will receive investigational medication and the assignment to the medication will be random.
The purpose of the ARAMIS trial is to determine the safety and effectiveness of ARAMIS to delay prostate cancer from spreading.
Talk with your doctor to find out if joining a clinical trial is right for you.
To learn more about the ARAMIS clinical trial l and to find out if you might be eligible to participate in the study, please visit: http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php (Trial Number: 17712) or https://clinicaltrials.gov/ct2/show/NCT02200614?term=ARAMIS&rank=2 (Study Identifier: NCT02200614) or contact Bayer Oncology Clinical Trial Navigation Service 844-229-3710 (toll free) www.oncologytrials.bayer.com